Who Is F. DuBois Bowman, the Next President of Morehouse?
Public health leader and biostatistician F. DuBois Bowman — who graduated from the institution in 1992 with a bachelor's degree in mathematics — will join the school as its 13th president at a time of great upheaval in higher education.
President Donald Trump has expressed a commitment to supporting HBCUs financially. But he has clashed publicly with schools like Harvard, Columbia, and the University of Pennsylvania. Trump has suspended or canceled some of their federal funding, while alleging that they allow antisemitism on their campuses or promote what he has called unlawful diversity, equity, and inclusion initiatives. The clashes have sown fear on college campuses nationwide, including among HBCUs, whose communities wonder whether their schools will become a target.
Bowman will start on July 15, Morehouse announced on Tuesday. He will succeed David A. Thomas, whose tenure ends in June following his resignation announcement last year.
'Dr. Bowman's record of visionary leadership, his deep commitment to academic excellence, and his lifelong dedication to Morehouse make him the ideal choice to lead the College into its next era,' said Willie Woods, chairman of the Morehouse College Board of Trustees, in a statement. 'He brings an extraordinary blend of intellectual rigor, strategic thinking, and values-driven leadership.'
During Thomas's tenure, he will be responsible for carrying out Morehouse's strategic plan, which calls, in part, for increasing the university's grant funding and developing partnerships with corporations, foundations, community entities, and other educational institutions.
On social media, followers and supporters of the Morehouse community expressed their support for Bowman.
'Super happy with Morehouse's pick for president,' wrote X user @kevcoke6. 'Not only is he a Morehouse man himself, he seems fit for the job.'
'I pray the Board of Trustees gives him space to work,' added X user @bullwinqle2.
Bowman has served as dean of the University of Michigan School of Public Health since 2018. A member of Omega Psi Phi Fraternity Inc. and the Phi Beta Kappa academic honor society, he maintained his connection to his alma mater through the facilitation of a University of Michigan pipeline program for Morehouse and Spelman College students. Morehouse awarded Bowman in 2019 with the Bennie Trailblazer Award, the school's highest alumni award, named for its sixth president, Benjamin Elijah Mays.
Bowman's research has 'transformed understanding of neurological and mental health disorders such as Parkinson's disease, Alzheimer's disease, depression, and schizophrenia,' according to the statement.
'Returning to Morehouse as its 13th president is the honor of a lifetime,' Bowman said. 'This institution shaped who I am — instilling a commitment to excellence, justice, and impact. I am excited to partner with faculty, staff, students, alumni, and supporters to build on our legacy and write the next chapter of Morehouse's transformative story.'
Bowman previously held academic and leadership positions at Columbia University and Emory University. He earned a master's degree in biostatistics from the University of Michigan and a doctorate in biostatistics from the University of North Carolina at Chapel Hill.
Bowman's wife, Cynthia, is a Spelman alumna. Their youngest son is currently enrolled at Morehouse, while another graduated from the school in 2024.
The post Who Is F. DuBois Bowman, the Next President of Morehouse? appeared first on Capital B News - Atlanta.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
12 hours ago
- UPI
FDA approves ketamine product for surgical pain management
The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management. Ketamine is the only psychedelic or psychedelic-adjacent drug on the World Health Organization Essential Medicines List, with its global market projected to grow from $750 million to $3.42 billion by 2034. PharmaTher, which developed KETARx, believes there is a promising outlook for the ketamine market and that the FDA approval provides a strong foundation for expanding the development of ketamine across diverse therapeutic areas. These areas include depression, neurological disorders (Parkinson disease, amyotrophic lateral sclerosis), and rare or chronic pain conditions. "Today marks a new chapter for PharmaTher. With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals. This historic FDA approval for PharmaTher is a testament to years of dedicated development, signaling a new era of growth," Fabio Chianelli, founder and CEO of PharmaTher, said in a statement. "We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders." Approval of KETARx was granted to PharmaTher. More Information Copyright © 2025 HealthDay. All rights reserved.
Yahoo
20 hours ago
- Yahoo
Trump tariffs backfiring on US textile exporters — what it could mean to America's manufacturing 'bounceback'
In January, President Donald Trump declared 'tariffs' to be 'the most beautiful word,' adding that his sweeping tariff plan would 'bring our country's businesses back.' But Jeff Bowman, CEO of Colorado-based Cocona Labs, doesn't see that happening in his own industry — textiles — or manufacturing in the U.S. more generally. Don't miss Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how I'm 49 years old and have nothing saved for retirement — what should I do? Don't panic. Here are 6 of the easiest ways you can catch up (and fast) Robert Kiyosaki warns of a 'Greater Depression' coming to the US — with millions of Americans going poor. But he says these 2 'easy-money' assets will bring in 'great wealth'. How to get in now Like Trump, he attended the Wharton School of Business, but told Bloomberg he suspects the president skipped the tariff class. 'The empirical history shows that when you impose tariffs, the net effect is that you reduce the amount of business that takes place,' he said. 'And we're seeing that happen already. Costs go up, consumers pay the price eventually.' Bowman is already experiencing it. Textiles in turmoil Cocona Labs produces a compound used in sustainable thermoregulation fabrics, but doesn't manufacture the fabrics themselves. Instead, the company ships batches of the compound to manufacturers around the world that produce the finished fabrics and products — from high-performance sports apparel to bedding. In turn, those countries export the textiles and fabrics back to the U.S. or sell them to their own domestic consumers. The problem is, the manufacturers are all in countries like China that Trump has hit with tariffs. In turn, those countries have imposed reciprocal tariffs on U.S. products — like Cocona Labs' compound. Stay in the know. Join 200,000+ readers and get the best of Moneywise sent straight to your inbox every week for free. Trump's tariffs and other countries' counter-tariffs are eating into Bowman's bottom line — making it tougher to keep costs down. In July, his company shipped a batch of the compound to China and absorbed 10% of the 16.5% tariff imposed on the product by China. 'That's not sustainable for us,' he said. 'Long term, we'd have to raise our prices. When we raise our prices, it will ultimately affect the amount of volume that's being sold. So it's not good.' Research suggests it's not good for consumers in the U.S. or abroad, raising prices for everyone and reducing sales. A 2024 Federal Reserve Board study found that the tariffs Trump imposed on other countries in his first term led to retaliatory taxes on U.S exports, 'hitting demand for the goods in many cases.' No bounceback yet Meanwhile, Trump's promised domestic manufacturing boom has yet to materialize. Certainly it hasn't boomed in Bowman's line of work. As the New York Times reports, the U.S. textile sector only employs a third of the 1.5 million Americans it once did. More generally, the manufacturing sector has actually shrunk in Trump's second term. The Institute for Supply Management (ISM) reports that U.S. manufacturing 'contracted in July for the fifth consecutive month,' along with employment in the industry, down for the sixth straight month. The Wall Street Journal notes while some companies are investing in U.S-based production — like Apple, which has committed $600 billion over the next four years — most companies won't make a capital commitment to set up a factory in the U.S. amid an ever-changing tariff landscape. With only 8% of the American workforce employed in manufacturing, economist and Harvard professor Robert Lawrence told CNN that the the sector will not be returning to the glory days of the late 1970s. 'These industrial and trade policies look like they were designed by an 80-year-old man who has nostalgia for the past when manufacturing was a real driver of employment opportunities,' he said of Trump's tariffs. What to read next Want an extra $1,300,000 when you retire? Dave Ramsey says this 7-step plan 'works every single time' to kill debt, get rich in America — and that 'anyone' can do it Here are 5 simple ways to grow rich with real estate if you don't want to play landlord. And you can even start with as little as $10 Rich, young Americans are ditching the stormy stock market — here are the alternative assets they're banking on instead Here are 5 'must have' items that Americans (almost) always overpay for — and very quickly regret. How many are hurting you? This article provides information only and should not be construed as advice. It is provided without warranty of any kind. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
a day ago
- CBS News
South Florida boxing program helps slow down Parkinson's disease symptoms, one punch at a time
About a million people have Parkinson's disease, according to the Parkinson's Foundation. And, medicine isn't the only way to help ease symptoms. Juan Rodriguez uses boxing to fight an opponent from within, which is Parkinson's disease. He told CBS News Miami that when he first started boxing, he had trouble walking and could barely stretch due to his diagnosis. "I wasn't able to do a lot," Rodriguez said. "I wasn't able to put on my socks correctly [and] I had a hard time tying my shoes." Now, he can wrap up his gloves and throw punches. He learned the essence of training: The more challenging the drill, the greater the progress. "This thing helped me a lot to do more than I wanted to," Rodriguez said. He's the youngest boxer at the Box with a Heart program at the Michael Ann Russell Jewish Community Center. It's part of the national Rock Steady Boxing program, which offers classes for people with Parkinson's. "He is an animal now," said Jennifer Enslign, who started the program nine years ago. "He runs. He does everything." She told CBS News Miami it's a year-round program because Parkinson's symptoms don't stop. She started the program because her husband has the disease. "I was looking for alternatives and therapies beyond medication and I said this is exactly what I need to do," Enslign said. The program started with just 12 boxers. Now it's helped nearly 300. Its mission has stayed the same: slow down Parkinson's symptoms one punch at a time. Now the program has retired boxer Francisco Palacios as a volunteer. He told CBS News Miami that the sport can help improve anyone's mobility, balance and hand-eye coordination. "The combinations help them balance themselves and their stability," Palacios said. "That's the first thing they lose when they get Parkinson's." Rodriguez said that because of boxing, he doesn't recognize the version of himself from three years ago. "It's a shock to me sometimes that I'm able to get this far," Rodriguez said. To their doctor's their patients, but here they are boxers.
